Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report)'s share price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $11.51 and traded as high as $12.47. Astria Therapeutics shares last traded at $11.87, with a volume of 356,408 shares changing hands.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on the stock. Wedbush reissued an "outperform" rating and set a $22.00 price objective on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Friday, September 27th. Oppenheimer upped their price objective on Astria Therapeutics from $25.00 to $26.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 13th. Evercore ISI upgraded Astria Therapeutics to a "strong-buy" rating in a report on Wednesday, August 14th. Finally, TD Cowen initiated coverage on Astria Therapeutics in a research note on Monday, July 29th. They issued a "buy" rating and a $35.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $25.20.
Check Out Our Latest Analysis on ATXS
Astria Therapeutics Stock Performance
The company has a fifty day moving average price of $11.50 and a two-hundred day moving average price of $10.54. The company has a market cap of $664.06 million, a P/E ratio of -5.12 and a beta of 0.71.
Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last posted its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.05). Research analysts anticipate that Astria Therapeutics, Inc. will post -1.68 EPS for the current year.
Institutional Trading of Astria Therapeutics
A number of large investors have recently added to or reduced their stakes in ATXS. Rhumbline Advisers boosted its stake in shares of Astria Therapeutics by 4.1% during the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company's stock worth $595,000 after acquiring an additional 2,556 shares during the period. Ameritas Investment Partners Inc. boosted its position in Astria Therapeutics by 135.6% during the first quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company's stock worth $70,000 after purchasing an additional 2,861 shares during the period. Quest Partners LLC boosted its position in Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 3,112 shares during the period. American International Group Inc. increased its holdings in shares of Astria Therapeutics by 49.4% in the first quarter. American International Group Inc. now owns 24,565 shares of the biotechnology company's stock valued at $346,000 after purchasing an additional 8,122 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Astria Therapeutics by 6.9% in the second quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company's stock valued at $1,266,000 after purchasing an additional 8,965 shares during the period. Institutional investors and hedge funds own 98.98% of the company's stock.
Astria Therapeutics Company Profile
(
Get Free Report)
Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.
See Also
Before you consider Astria Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astria Therapeutics wasn't on the list.
While Astria Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
